Search results
Results from the WOW.Com Content Network
Atomoxetine, formerly sold under the brand name Strattera [12], is a selective norepinephrine reuptake inhibitor ... In adults, efficacy and tolerability are equivalent.
The slow and long-acting nonstimulant atomoxetine (Strattera), is primarily a norepinephrine reuptake inhibitor and, to a lesser extent, a dopamine reuptake inhibitor. [14] It is sometimes prescribed in adults who do not get enough vigilant concentration response from mixed amphetamine salts (Adderall) or get too many side effects.
Atomoxetine is a selective norepinephrine reuptake inhibitor. [85] It has comparable efficacy, tolerability and response rate to methylphenidate in children and adolescents; efficacy and discontinuation rate is equivalent in adults.
More specifically, it looked at the effect of methylphenidate (brand names Ritalin, Concerta), a stimulant, and atomoxetine (Strattera), a non-stimulant, on the brain.
Adult Attention Deficit Hyperactivity Disorder is the persistence of attention deficit hyperactivity disorder (ADHD) into adulthood. It is a neurodevelopmental disorder, meaning impairing symptoms must have been present in childhood, except for when ADHD occurs after traumatic brain injury.
Atomoxetine has been shown to significantly improve academic performance. [295] [296] Meta-analyses and systematic reviews have found that atomoxetine has comparable efficacy, equal tolerability and response rate (75%) to methylphenidate in children and adolescents. In adults, efficacy and discontinuation rates are equivalent. [297] [298] [299 ...
However, two more recent studies by Barkley found that while children and adults with CDS had some deficits in executive functions (EF) in everyday life activities, they were primarily of far less magnitude and largely centered around problems with self-organization and problem-solving. Even then, analyses showed that most of the difficulties ...
Atomoxetine is sold under the brand name Strattera and was first approved for medical use in the United States in 2002. [1] Its indication is for the treatment of attention deficit hyperactivity disorder (ADHD) in children over 6 years of age, adolescents and adults. [2]